- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06892691
Pleuroskopi først versus thoracentese først hos patienter med mistanke om ondartede pleurale effusioner (PERFECT-MPE)
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. Both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. Currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. This study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. Patients will be recruited and randomized in a 1:1 manner.
Ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. Any other imaging will be determined by clinic need only. No imaging will be done for research purposes. No additional samples will be collected other than what is necessary for diagnostic purposes. In patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. In the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) The need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10019
- Mount Sinai West
-
New York, New York, Forenede Stater, 10029
- Mount Sinai Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Referral for diagnostic pleural procedure.
- Age ≥ 18 years.
- Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.)
Exclusion Criteria:
- Inability to provide informed consent.
- Needs emergent drainage.
- Pleural effusion is known to be malignant.
- Suspected transudative, infectious or inflammatory effusion etiology.
- Having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy.
- Patient is deemed by the clinical team to be more appropriate for VATS biopsy.
- Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities.
- Pregnancy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Pleuroscopy first
Participants will undergo pleuroscopy first |
Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis. |
|
Aktiv komparator: Thoracentesis first
Participants will undergo thoracentesis first |
Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of biopsies adequate for definitive diagnosis
Tidsramme: 6 months
|
Proportion of biopsies adequate for definitive diagnosis |
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time from initial visit with pulmonologist to procedure
Tidsramme: 6 months
|
Time from initial visit with pulmonologist to procedure |
6 months
|
|
Time from initial procedure to diagnosis
Tidsramme: 6 months
|
Time from initial procedure to diagnosis |
6 months
|
|
Time from initial visit with pulmonologist to diagnosis
Tidsramme: 6 months
|
Time from initial visit with pulmonologist to diagnosis |
6 months
|
|
Time from initial visit with pulmonologist to seeing oncologist
Tidsramme: 6 months
|
Time from initial visit with pulmonologist to seeing oncologist |
6 months
|
|
Time from initial visit with pulmonologist to starting treatment
Tidsramme: 6 months
|
Time from initial visit with pulmonologist to starting treatment |
6 months
|
|
Time from seeing oncologist to starting treatment
Tidsramme: 6 months
|
Time from seeing oncologist to starting treatment |
6 months
|
|
Frequency of procedure-related complications
Tidsramme: 6 months
|
Frequency of procedure-related complications |
6 months
|
|
Frequency of additional diagnostic testing
Tidsramme: 6 months
|
Frequency of additional diagnostic testing |
6 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Udit Chaddha, MBBS, MOUNT SINAI HOSPITAL
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY-24-00999
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All of the individual participant data collected during the trial, after deidentification.
IPD-delingstidsramme
Immediately following publication. No end date.
IPD-delingsadgangskriterier
Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose.
Any purpose. Proposals should be directed to udit.chaddha@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link tbd).
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .